ATMI and Sartorius Stedim Biotech Extend Global Supply and Marketing Alliance
ATMI, Inc. (Danbury, CT), and Sartorius Stedim Biotech S.A. (Aubagne, France) have extended their marketing and distribution alliance by adding new technologies.
ATMI, Inc. (Danbury, CT), and Sartorius Stedim Biotech S.A. (Aubagne, France) have extended their marketing and distribution alliance by adding new technologies. The new agreement grants global marketing and distribution rights to ATMI's patented Magnetic Mixer technology to Sartorius. ATMI's Magnetic Mixer is a mobile, mixing system designed for mixing applications in various volumes. It is used in biopharmaceutical processes that require powerful mixing torque, such as buffer and media preparation, and final product formulation applications.
Under the extended agreement, Sartorius retains continued distribution and marketing rights to ATMI LifeSciences' LevMixer mixing system technology that Sartorius has been marketing since April 2008. The LevMixer system is a single-use mixing system that uses patented technology to levitate and drive a single-use impeller inside sterile bags. It mainly is used for liquid-to-liquid applications in downstream purification and sensitive formulation steps, as well as easy-to-dissolve powders, such as salts and buffers.
The expanded agreement also grants Sartorius rights to ATMI's portfolio of bioreactor-related intellectual property, which allows Sartorius to further enable its line of BIOSTAT CultiBag STR single-use bioreactors.
The supply and marketing agreement is a five-year global agreement containing an additional five-year continuity-of-supply clause.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
